{"transactions":[{"id":726442,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T22:00:08.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":6068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":6068,"derivative":{"exercise_price":99.87,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":6068},"source":{"system":"sec-edgar","filing":"0001193125-26-283140","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526283140/ownership.xml","form_type":"4"}},{"id":728552,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:27:31.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001821194-26-000002","document":"form4-06232026_090627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000182119426000002/form4-06232026_090627.xml","form_type":"4"}},{"id":1101118,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T01:00:13.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":16000,"derivative":{"exercise_price":46.47,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-090584","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025090584/ownership.xml","form_type":"4"}},{"id":1110978,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:23.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017236","document":"form4-06132025_050619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588925017236/form4-06132025_050619.xml","form_type":"4"}},{"id":1473317,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T21:00:10.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 18, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":16000,"derivative":{"exercise_price":31.2,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-24-075710","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017024075710/ownership.xml","form_type":"4"}},{"id":1474408,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T21:00:17.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":23000,"derivative":{"exercise_price":12.36,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001415889-24-017445","document":"form4-06182024_050613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924017445/form4-06182024_050613.xml","form_type":"4"}},{"id":1669622,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-26T16:44:21.000Z","date":"2024-01-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.44,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001999371-24-000969","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724979/000199937124000969/ownership.xml","form_type":"4"}},{"id":1669621,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-26T16:44:21.000Z","date":"2024-01-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. (\"Parent\") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), dated as of December 13, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.21,"underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001999371-24-000969","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724979/000199937124000969/ownership.xml","form_type":"4"}},{"id":1809955,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T21:07:10.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 35,000 shares of the Issuer's common stock, which will vest in full on the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":35000,"derivative":{"exercise_price":1.21,"expiration_date":"2033-08-09","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-23-090699","document":"tm2323614-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724979/000110465923090699/tm2323614-4_4seq1.xml","form_type":"4"}},{"id":1847422,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T21:00:28.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":21520,"derivative":{"exercise_price":7.84,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-23-010102","document":"form4-06212023_050605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923010102/form4-06212023_050605.xml","form_type":"4"}},{"id":1849728,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T20:15:09.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":12000,"derivative":{"exercise_price":27.67,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-23-015960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924323015960/doc4.xml","form_type":"4"}},{"id":2178315,"issuer":{"id":94695,"kind":"organization","name":"Rain Oncology Inc.","symbol":"RAIN"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-19T17:34:04.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 20,000 shares of the Issuer's common stock, which will vest in full on June 1, 2023, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":20000,"derivative":{"exercise_price":2.44,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-029312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724979/000089924322029312/doc4.xml","form_type":"4"}},{"id":2220834,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-27T21:08:26.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is \"June 17, 2022\" and the correct exercise price is \"$3.61\" as shown herein."},{"field":"date","element":"transactionDate","label":"F1","text":"This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is \"June 17, 2022\" and the correct exercise price is \"$3.61\" as shown herein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":3.61,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-22-006960","document":"form4a-06272022_020605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588922006960/form4a-06272022_020605.xml","form_type":"4/A","original_submission_date":"2022-06-17"}},{"id":2226477,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T23:29:53.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":3.43,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-22-006785","document":"form4-06172022_040645.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588922006785/form4-06172022_040645.xml","form_type":"4"}},{"id":2230129,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T20:06:10.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2023 and (ii) the date of the next annual meeting of the Issuer's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":12000,"derivative":{"exercise_price":14.18,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-22-022797","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924322022797/doc4.xml","form_type":"4"}},{"id":2664098,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T20:48:08.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":20063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 16, 2022 and (ii) the date of the next annual meeting of the Issuer's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":20063,"derivative":{"exercise_price":49.1,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":20063},"source":{"system":"sec-edgar","filing":"0000899243-21-024442","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924321024442/doc4.xml","form_type":"4"}},{"id":2673216,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-10T22:43:00.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 9, 2021, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":27.66,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-21-002929","document":"form4-06102021_030646.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921002929/form4-06102021_030646.xml","form_type":"4"}},{"id":2972608,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:46:38.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to the Reporting Person's continuous service through each applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":21520,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001209191-20-059516","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059516/doc4.xml","form_type":"4"}},{"id":2972607,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:46:38.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to the Reporting Person's continuous service through each applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":21520,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001209191-20-059516","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059516/doc4.xml","form_type":"4"}},{"id":2972606,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:46:38.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":21520,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001209191-20-059516","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059516/doc4.xml","form_type":"4"}},{"id":3050064,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":35407,"kind":"person","name":"Hrustanovic Gorjan","position":1,"cik":"0001821194","reported_name":"Hrustanovic Gorjan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-21T22:26:18.000Z","date":"2020-08-20","kind":"grant","acquired":true,"shares":40127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on the date of the Registration Statement Effectiveness."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person is a member of BVF Partners L.P. (\"BVF\") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any."}],"balance_after":40127,"derivative":{"exercise_price":20,"expiration_date":"2030-08-19","underlying":"Common Stock","underlying_shares":40127},"source":{"system":"sec-edgar","filing":"0000899243-20-023235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924320023235/doc4.xml","form_type":"4"}}]}